Intervacc agrees on contract manufacturing
Intervac has, on April 4th, 2012, signed an agreement with IDT-Biologika (Dessau, Germany) about contract manufacturing of Strangvac®.
Read more...
 
Strangvac® in new final studies
In September 2011 Intervacc initiated the first duration study of the protective effect of Strangvac® at the Animal Health Trust, AHT, in Newmarket. The protective effect elicited by Strangvac against equine strangles will be investigated in experimentally infected horses three months after finalised basic vaccination program. The results will be ready in May 2012.
Read more...
 
Strangvac® results of new study – The vaccine protects also at a low dose
The results are very encouraging in that it was found that a very low dose of antigen led to the same level of protection as using ten times higher.
Read more...
 

 

CONTACT US: Tel. +46 (8) 120 10 600 E-mail: info@intervacc.se